Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Precancerous Conditions 1Oropharyngeal Neoplasms 1Mouth Neoplasms 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Head and Neck Neoplasms 1Cardiotoxicity 1Breast Neoplasms, Male 1Breast Neoplasms 1

Interventions

Doxorubicin 17Echocardiography 14Exercise 9Cyclophosphamide 9Trastuzumab 8Dexrazoxane 8Electrocardiography 7Razoxane 6Carvedilol 6Vincristine 4Radiotherapy 4Filgrastim 4Docetaxel 4Methotrexate 3Granulocyte Colony-Stimulating Factor 3Etoposide 3Cisplatin 3Atorvastatin 3salicylhydroxamic acid 2sacubitril and valsartan sodium hydrate drug combination 2empagliflozin 2dapagliflozin 2Tablets 2Social Determinants of Health 2Silymarin 2Prednisone 2Paclitaxel 2Neoadjuvant Therapy 2Magnetic Resonance Spectroscopy 2Leucovorin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cardiotoxicity × Fluorophotometry × Clear all
NCT00436566 2022-08-05

Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery

Mayo Clinic

Phase 2 Completed
122 enrolled 22 charts
Breast

Breast Neoplasms, Breast Neoplasms, Male, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡